1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
3.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and under
Sponsor: NCI
Protocol IDs: FHCRC-2130.00, 6447, NCT00445744
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-009, NCT00481871
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCI-07-C-0195, 07-C-0195, NCT00520130
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
7.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 100
Sponsor: Other
Protocol IDs: BCM-H-12472, H 12472, BCM-ACHE, NCT00056966
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC078B, MC078B, NCT00669578
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 to 75
Sponsor: NCI
Protocol IDs: UNMC-16407, 164-07, NCT00816413
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-03, NCT00858572
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12175A, NCT00943293
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13437B, NCT00943319
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 14341B, NCT00943592
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 76
Sponsor: Other
Protocol IDs: 06-954, NCT00957359
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-103, NCT00975767
|
|
18.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCL09101, NCT00935987
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: NHLBI-99-H-0050, NCT00003838
|
|
20.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: NCI-04-C-0055, NCT00077480
|
|
21.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1898.00, 5788, NCT00089011
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 70 years
Sponsor: NCI
Protocol IDs: JHOC-J0457, JHOC-04072704, NCT00134004
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J0638, J0638, 7704, NCI-7704, NCT00381550
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-2056.00, 6171, NCT00397813
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 to 75
Sponsor: NHLBI
Protocol IDs: NHLBI-06-H-0248, NHLBI-IDE-13058, NCT00398346
|
